Chipscreen(SH:688321) Zheng Quan Zhi Xing·2025-08-22 10:18Core Viewpoint - Shenzhen Chipscreen Co., Ltd. is preparing for a specific issuance of A-shares in 2024, with the underwriting by Guotou Securities, emphasizing its commitment to compliance and due diligence in the process [1][2]. Company Overview - Shenzhen Chipscreen Co., Ltd. was established on March 21, 2001, with a registered capital of 408.54 million yuan and is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board under the stock code 688321 [5]. - The company focuses on providing affordable, clinically needed innovative drugs, with a complete capability from drug discovery to commercialization [3]. Main Business - The company has products in commercialization, with core pipelines undergoing global registration clinical trials. Its main products include: - Westabamine: Approved for multiple cancers in China, Japan, and Taiwan, recognized as a first-line treatment for certain lymphomas [4][7]. - Sigraglitazone: Approved for Type 2 diabetes and included in medical insurance, with plans to promote its unique advantages in metabolic disease management [4][17]. Research and Development - The company has a robust R&D team of 272 personnel, with a high percentage holding advanced degrees, focusing on innovative drug discovery [5]. - As of March 31, 2025, the company holds 191 authorized invention patents, ensuring a comprehensive global patent strategy to protect its products [6]. Financial Data - As of March 31, 2025, the total assets of the company amounted to 3.31 billion yuan, with total liabilities of 1.75 billion yuan and equity attributable to shareholders of 1.56 billion yuan [23]. - For the first quarter of 2025, the company reported an operating income of 162.26 million yuan, with a net profit attributable to shareholders of -19.15 million yuan [23]. Clinical Trials and Product Pipeline - The company is advancing several clinical trials, including: - Westabamine: Involved in multiple Phase III trials for various cancers, showing promising results in combination therapies [12][14]. - Sigraglitazone: Demonstrated significant efficacy in controlling blood sugar levels and improving lipid metabolism in Type 2 diabetes patients [18][19]. - Xiaoroni: A multi-target kinase inhibitor currently in clinical trials for pancreatic and ovarian cancers [20][21]. Market Position and Strategy - The company aims to transform "cold tumors" into "hot tumors" to enhance immunotherapy responses, positioning itself strategically in the oncology market [15]. - Collaborations with international partners for global development and commercialization of its products are underway, marking a significant step in expanding its market reach [16].